Successful vaccine-induced seroconversion by single-dose immunization in the presence of measles virus-specific maternal antibodies
about
Recombinant vesicular stomatitis virus vaccine vectors expressing filovirus glycoproteins lack neurovirulence in nonhuman primatesVesicular stomatitis virus-based ebola vaccine is well-tolerated and protects immunocompromised nonhuman primatesDevelopment of a new vaccine for the prevention of Lassa fever.Characterization of vesicular stomatitis virus recombinants that express and incorporate high levels of hepatitis C virus glycoproteins.Generation of hepatitis C virus-like particles by use of a recombinant vesicular stomatitis virus vectorVesicular stomatitis virus vectors expressing avian influenza H5 HA induce cross-neutralizing antibodies and long-term protection.Lower levels of gamma interferon expressed by a pseudotyped single-cycle simian immunodeficiency virus enhance immunogenicity in rats.Vaccination with hemagglutinin or neuraminidase DNA protects BALB/c mice against influenza virus infection in presence of maternal antibody.A single immunization with a dry powder anthrax vaccine protects rabbits against lethal aerosol challengeRefined methods for propagating vesicular stomatitis virus vectors that are defective for G protein expression.Protection against lethal vaccinia virus challenge by using an attenuated matrix protein mutant vesicular stomatitis virus vaccine vector expressing poxvirus antigens.Glycoprotein exchange vectors based on vesicular stomatitis virus allow effective boosting and generation of neutralizing antibodies to a primary isolate of human immunodeficiency virus type 1A chimeric human-bovine parainfluenza virus type 3 expressing measles virus hemagglutinin is attenuated for replication but is still immunogenic in rhesus monkeys.Replication-competent or attenuated, nonpropagating vesicular stomatitis viruses expressing respiratory syncytial virus (RSV) antigens protect mice against RSV challenge.Live attenuated recombinant vaccine protects nonhuman primates against Ebola and Marburg viruses.A single-cycle vaccine vector based on vesicular stomatitis virus can induce immune responses comparable to those generated by a replication-competent vector.A vesicular stomatitis virus recombinant expressing granulocyte-macrophage colony-stimulating factor induces enhanced T-cell responses and is highly attenuated for replication in animalsHigh-level primary CD8(+) T-cell response to human immunodeficiency virus type 1 gag and env generated by vaccination with recombinant vesicular stomatitis viruses.Influence of maternal antibodies on neonatal immunization against respiratory viruses.The hemagglutinin of canine distemper virus determines tropism and cytopathogenicity.Recombinant vesicular stomatitis virus vectors expressing herpes simplex virus type 2 gD elicit robust CD4+ Th1 immune responses and are protective in mouse and guinea pig models of vaginal challenge.Synergistic induction of interferon α through TLR-3 and TLR-9 agonists stimulates immune responses against measles virus in neonatal cotton ratsAttenuated Salmonella enterica serovar Typhi and Shigella flexneri 2a strains mucosally deliver DNA vaccines encoding measles virus hemagglutinin, inducing specific immune responses and protection in cotton rats.Insights into the regulatory mechanism controlling the inhibition of vaccine-induced seroconversion by maternal antibodies.Neurovirulence properties of recombinant vesicular stomatitis virus vectors in non-human primatesVesicular stomatitis virus-based therapeutic vaccination targeted to the E1, E2, E6, and E7 proteins of cottontail rabbit papillomavirusMeasles virus-specific CD4 T-cell activity does not correlate with protection against lung infection or viral clearance.Attenuation of recombinant vesicular stomatitis virus-human immunodeficiency virus type 1 vaccine vectors by gene translocations and g gene truncation reduces neurovirulence and enhances immunogenicity in miceComplete protection from papillomavirus challenge after a single vaccination with a vesicular stomatitis virus vector expressing high levels of L1 protein.Single-dose, virus-vectored vaccine protection against Yersinia pestis challenge: CD4+ cells are required at the time of challenge for optimal protection.Generation of a More Immunogenic Measles Vaccine by Increasing Its Hemagglutinin Expression.Sindbis virus-based measles DNA vaccines protect cotton rats against respiratory measles: relevance of antibodies, mucosal and systemic antibody-secreting cells, memory B cells, and Th1-type cytokines as correlates of immunityHuman immunodeficiency virus type 1 elite neutralizers: individuals with broad and potent neutralizing activity identified by using a high-throughput neutralization assay together with an analytical selection algorithm.Characterization of nonpathogenic, live, viral vaccine vectors inducing potent cellular immune responses.Single injection recombinant vesicular stomatitis virus vaccines protect ferrets against lethal Nipah virus disease.RNA-based viral vectors.Vesicular stomatitis virus genomic RNA persists in vivo in the absence of viral replication.Cytokine-modified VSV is attenuated for neural pathology, but is both highly immunogenic and oncolytic.A Recombinant Measles Vaccine with Enhanced Resistance to Passive Immunity.Replication and propagation of attenuated vesicular stomatitis virus vectors in vivo: vector spread correlates with induction of immune responses and persistence of genomic RNA.
P2860
Q21090120-32965884-564E-4F36-B6F1-97140ADFE36CQ21131585-4C3136DD-AC94-43B9-871A-28647C7D691AQ21563440-14B34BF8-9B91-4E33-BB0A-C596C68009B3Q27472885-2C56D024-CE84-40F7-AE0A-3391CA064717Q27472940-52F2ACAB-D324-4FE7-9E9E-57811135056AQ30361939-BF5E8043-7E13-4FE8-B8EE-6E43CC399CBEQ30373857-7CAFACA6-2DDE-463C-8589-7EBEA3305D1DQ33302857-2ECAD1AB-BE9A-43E5-BB84-E29B34A178E6Q33360151-C0D26E27-DB5F-4473-AE2E-ECBD6F9D98F8Q33721746-C8711E2D-CF4F-4E4B-BE48-EDA84CECC6C1Q33725635-B4E77472-0361-4466-BB56-14FC4B1EE2DDQ33826382-85877082-B7C8-4D11-AFE7-0C0931E218B8Q33848343-4A23831D-532F-4BF6-99C0-1247AC1EF154Q33849224-D5CDF674-DA15-4FD6-BD6D-BFC8E420DA2FQ33987611-79CE1995-5C77-4059-9B63-190EBCD7F533Q34092753-27AB6A2E-B428-4A83-AFA0-27D094F9CD76Q34228558-0A5CFFD8-28AE-49CD-B275-54C6E84C86D5Q34333167-CB80E357-8506-457A-AE71-301F7E836F60Q34398563-FAD11264-17CF-48C0-9396-98E14BD6FE04Q34515872-A7F4FC68-07CC-4EBF-8B80-D72D22E5ACE6Q34647625-7F638C85-CB09-4C7D-A325-C8787FD12274Q34820590-8114D3F5-9E7C-4C92-B125-851BFFACD575Q34976024-9E36BC33-9F70-4B3A-ACE5-ED1549733B42Q35067373-F818C5BE-FE80-4F94-BD12-0AF3614E7F5BQ35781967-07BFE5AC-CD63-4FB8-8629-05DDBF33E992Q35857789-3A6BE80C-042D-4385-BDD5-E0D7AA6F401DQ35947792-96A1A7D2-B407-405C-A376-DE263F145387Q36423935-4A4B399B-AA33-4FAB-9212-19F7F78D5807Q36509916-BCE07D13-804A-4D6A-B46B-DF2CE6FE85BEQ37066697-FE8819CA-40DE-4CA7-9EF1-002B6CE6162BQ37069798-80442A2F-9D6E-49D6-901B-11C5F4BDA1DBQ37110690-96C7D0D1-9513-4831-9DCB-09C09D889E7FQ37247974-EFAB624C-1E96-4263-8C83-557D54EA7DAFQ37348721-740AF032-F9DE-43E0-97DA-ED751D174774Q37427047-BAEAACD5-FED3-4136-8BC6-B10B3B548D73Q38266413-F380DE5B-7574-4E10-B4DA-475D49C3BDF2Q39610541-20A7B8C6-F4A7-47BB-B58D-97D770D2FF07Q41829468-F92D4689-2F22-49B1-8BAC-1F8B82D786D6Q41933011-C034DF16-1292-4CC1-AFCF-C7A9B5C1BBE5Q42036085-0043E853-3710-455A-8B79-A208C3038862
P2860
Successful vaccine-induced seroconversion by single-dose immunization in the presence of measles virus-specific maternal antibodies
description
2000 nî lūn-bûn
@nan
2000 թուականի Մայիսին հրատարակուած գիտական յօդուած
@hyw
2000 թվականի մայիսին հրատարակված գիտական հոդված
@hy
2000年の論文
@ja
2000年論文
@yue
2000年論文
@zh-hant
2000年論文
@zh-hk
2000年論文
@zh-mo
2000年論文
@zh-tw
2000年论文
@wuu
name
Successful vaccine-induced ser ...... s-specific maternal antibodies
@ast
Successful vaccine-induced ser ...... s-specific maternal antibodies
@en
type
label
Successful vaccine-induced ser ...... s-specific maternal antibodies
@ast
Successful vaccine-induced ser ...... s-specific maternal antibodies
@en
prefLabel
Successful vaccine-induced ser ...... s-specific maternal antibodies
@ast
Successful vaccine-induced ser ...... s-specific maternal antibodies
@en
P2093
P2860
P921
P1433
P1476
Successful vaccine-induced ser ...... s-specific maternal antibodies
@en
P2093
B Schlereth
L Buonocore
S Niewiesk
P2860
P304
P356
10.1128/JVI.74.10.4652-4657.2000
P577
2000-05-01T00:00:00Z